Emman Shubbar

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Assessment of potential nephrotoxicity biomarkers after [177Lu]Lu-DOTA-(Tyr3)-octreotate administration and effects of antioxidant α1-microglobulin.

Assessment of potential nephrotoxicity biomarkers after [177Lu]Lu-DOTA-(Tyr3)-octreotate administration and effects of antioxidant α1-microglobulin.

Journal: Scientific reports
Published: January 22, 2026

Late apoptotic effects after treatment with 177Lu-octreotate in small-intestine neuroendocrine GOT1 tumor model.

Late apoptotic effects after treatment with 177Lu-octreotate in small-intestine neuroendocrine GOT1 tumor model.

Journal: International journal of radiation biology
Published: August 12, 2025

Effects of Recombinant α1-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177Lu-Octreotate.

Effects of Recombinant α1-Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177Lu-Octreotate.

Journal: International journal of molecular sciences
Published: May 23, 2024

Short and long-term effects on the thyroid proteome after 131I exposure.

Short and long-term effects on the thyroid proteome after 131I exposure.

Journal: Radiation protection dosimetry
Published: April 03, 2024

Early apoptotic response in kidney after 177Lu-octreotate administration with or without potential radioprotector α1-microglobulin.

Early apoptotic response in kidney after 177Lu-octreotate administration with or without potential radioprotector α1-microglobulin.

Journal: Radiation protection dosimetry
Published: March 11, 2024

Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors.

Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors.

Journal: Scientific reports
Published: April 19, 2022

Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model.

Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model.

Journal: Cancers
Published: November 10, 2021

Correction: Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure.

Correction: Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure.

Journal: PloS one
Published: October 27, 2021

Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate.

Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate.

Journal: BMC cancer
Published: March 01, 2021

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure.

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure.

Journal: PloS one
Published: May 25, 2020

Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.

Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.

Journal: PloS one
Published: January 14, 2020

Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.

Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.

Journal: PloS one
Published: March 18, 2019
Showing 1-12 of 21

Last Updated: 09/26/2026